Accessible Search Form           Advanced Search

9. Research Grants


NHLBI Research Grants by Funding Mechanism:  Fiscal Year 2009

Research Project Grants (RPGs)

Number of
Grants

Total Cost
(Dollars in Thousands)

Percent of
Total NHLBI
Research
Grant Dollars

Research Project Grants (Excluding Small Business RPGs)

 

 

 

Regular Research Grants (R01)

3,098

$1,350,194

59.72%

Program Project Grants (P01)

156

320,690

14.18

Cooperative Agreements (U01)

201

182,392

8.07

Exploratory Developmental Grants (R21)

248

52,615

2.33

Method to Extend Research in Time (R37)

71

31,450

1.39

Exploratory/Developmental Grants Phase II (R33)

29

9,251

0.41

AREA Grants (R15)

15

3,262

0.14

Research Transition Award (R00)

33

8,166

0.36

Cooperative Agreements (U19)

1

1,808

0.08

Small Research Grants (R03)

43

2,085

0.09

NIH Director's Pioneer Award (DP1)

1

1,607

0.07

Subtotal, Research Project Grants (Excluding Small Business RPGs)

3,896

1,963,520

86.84

Small Business Research Project Grants

 

 

 

Small Business Technology Transfer (STTR Phase I) (R41)

8

1,753

0.08

Small Business Technology Transfer (STTR Phase II) (R42)

12

7,072

0.31

Small Business Innovation Research (SBIR Phase I) (R43)

60

11,182

0.49

Small Business Innovation Research (SBIR Phase II) (R44)

92

56,334

2.49

Subtotal, Small Business Research Project Grants

172

76,341

3.37

Subtotal, Research Project Grants

4,068

2,039,861

90.21

Research Center Grants

 

 

 

Specialized Centers of Clinical Research (SCCOR) (P50)

23

65,227

2.88

Sickle Cell Centers (U54)

15

13,567

0.60

Center for AIDS Research (P30)

3,254

0.14

Specialized Centers (Cooperative Agreements) (U54)

5

7,649

0.34

National Swine Research and Resource Center (U42)

455

0.02

Subtotal, Research Center Grants

43

90,152

3.98

Research Career Programs

 

 

 

Mentored Research Development Award for Minority Faculty (K01)

37

4,745

0.21

Minority Institution Faculty Mentored Research Scientist Award (K01)

5

663

0.03

Mentored Scientist Development Award in Research Ethics (K01)

1

165

0.01

Independent Scientist Award (K02)

19

1,880

0.08

Pediatric Transfusion Medicine Academic Award (K07)

4

486

0.02

Cultural Competence & Health Disparities Academic Award (K07)

9

1,138

0.05

Clinical Investigator Scientist Award (K08)

231

29,706

1.31

Vascular Medicine Research Career Development Program (K12)

7

7,325

0.32

Clinical Hematology Research Career Development Program (K12)

6

2,375

0.11

Genetics and Genomics of Lung Disease Career Development Program (K12)

8

3,190

0.14

Career Enhancement Award for Stem Cell Research (K18)

3

477

0.02

Career Transition Award (K22)

1

162

0.01

Mentored Patient-Oriented Research Career Development Award (K23)

149

20,831

0.92

Midcareer Investigator Award in Patient-Oriented Research (K24)

32

5,078

0.22

Mentored Quantitative Research Career Development Award (K25)

14

1,996

0.09

Career Transition Award (K99)

46

4,430

0.20

Subtotal, Research Career Programs

572

84,647

3.75

Other Research Grants

Cooperative Clinical Research (U10, R10)

23

18,775

0.83

Minority Biomedical Research Support (S06, R25, SC2)

9

2,167

0.10

Other (R09, R13, R18, R24, R25, T15, U09, U24, UH1)

112

25,412

1.12

Subtotal, Other Research Grants

144

46,354

2.05

Total, NHLBI Research Grants

4,827

$2,261,014

100%

NHLBI Total Research Grants by Category

NHLBI Total Research Grants by Category
Text-only with data points

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations:  Fiscal Years 1999–2009

NHLBI Research Project Grant,* Research Centers Grant, and Other Research Grant Obligations
Text-only with data points are represented in the table below.

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.
** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Research Project Grants,* Research Centers Grants, and Other Research Grant Obligations:  Fiscal Years 1999–2009

Dollars (Thousands)

 

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

Research Project Grants*

$1,142,473

$1,356,034

$1,580,751

$1,779,573

$1,920,201

$2,003,769

$2,042,050

$2,011,049

$1,986,692

$1,983,633

$2,039,861

Research Centers Grants

119,889

123,803

127,232

128,161

138,941

140,600

151,495

141,086

141,034

107,393

90,152

Other Research Grants**

84,219

90,666

88,958

98,460

113,172

112,785

116,713

123,802

135,284

125,942

131,001

Total

$1,346,581

$1,570,503

$1,796,941

$2,006,194

$2,172,314

$2,257,154

$2,310,258

$2,275,937

$2,263,010

$2,216,968

$2,261,014

*Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.
** Includes Research Career Programs; excludes General Research Support Grants.

NHLBI Competing Research Project Grant Applications:* Fiscal Years 1999–2009

Number Reviewed and Awarded

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 1998-2008
Text-only with data points are represented in the table below.

Number Reviewed and Awarded and Percent Funded

 

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

Applications Reviewed

2,704

2,893

2,895

3,064

3,098

3,548

3,865

4,412

4,504

4,492

4,373

RPGs Awarded

959

1,003

1,033

1,018

1,064

1,034

909

871

943

997

968

Success Rate (percent)

35.5

34.7

35.7

33.2

34.3

29.1

23.5

19.7

20.9

22.2

22.1

*  Includes R01, U01, P01, R03, R15, R21, R29, and R37; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.

Percent of Reviewed Applications Funded (Success Rate)

NHLBI Competing Research Project Grant Applications*:  Fiscal Years 1998-2008
Text-only with data points are represented in the table above.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1999–2009

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1998-2008
Text-only with data points are represented in the table below.

* Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Investigator-Initiated and Institute-Initiated Grant Obligations:  Fiscal Years 1999–2009

Dollars (Millions)

 

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

Investigator-Initiated*

$1,069.9

$1,241.6

$1,446.2

$1,584.9

$1,681.9

$1,773.4

$1,822.9

$1,802.1

$1,774.8

$1,820.8

$1,850.1

Institute-Initiated**

276.7

328.9

350.7

421.3

490.4

483.8

487.3

473.8

488.2

396.1

410.9

Total

$1,346.6

$1,570.5

$1,796.9

$2,006.2

$2,172.3

$2,257.2

$2,310.2

$2,275.9

$2,263.0

$2,216.9

$2,261.0

* Includes RPGs, SBIRs/STTRs, Research Career Programs, and Other Research.
** Includes RPGs, Centers Grants, Research Career Programs, Other Research, and Cooperative Agreement RFAs.

NHLBI Research Project Grants:*  Amount Funded by Type of Award, Fiscal Years 1999–2009

Dollars (Millions)

 

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

Competing

 

 

 

 

 

 

 

 

 

 

 

  New Competing

$   202.0

$   266.4

$   280.0

$   291.2

$   285.5

$   290.5

$   270.0

$   242.9

$   330.9

$   314.2

$ 340.2

  Renewal Competing

127.2

152

143.9

143.9

177.2

185.5

176.1

168.3

169.4

196.9

172.6

  Competing
  Supplements

1.2

0.9

0.4

2.3

1

1.3

1.7

0.4

1.7

0.3

Subtotal, Competing

330.4

419.3

424.3

437.4

463.7

477.3

447.8

411.6

500.3

512.8

513.1

Noncompeting

 

 

 

 

 

 

 

 

 

 

 

Subtotal, Noncompeting

770.6

889.3

1,101.5

1,281.3

1,390.3

1,454.9

1,520.0

1,527.0

1,486.4

1,470.8

1,526.8

Total, Competing and Noncompeting

$1,101.0

$1,308.6

$1,525.8

$1,718.7

$1,854.0

$1,932.2

$1,967.8

$1,938.6

$1,986.7

$1,983.6

$2,039.9

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.

Facility and Administrative (F&A) Costs of NHLBI Research Project Grants:* Fiscal Years 1999–2009

Dollars (Thousands)

Fiscal Year

Direct Cost

F&A Cost

Total Cost

F&A Cost as a
Percent of Direct Cost

1999

764,198

336,756**

1,100,954

44.1

2000

891,244

417,312

1,308,556

46.8

2001

1,045,144

480,673

1,525,817

46.0

2002

1,182,408

536,324

1,718,732

45.4

2003

1,276,819

577,131

1,853,950

45.2

2004

1,329,106

603,133

1,932,239

45.4

2005

1,355,803

612,007

1,967,810

45.1

2006

1,334,406

604,183

1,938,589

45.3

2007

1,378,134

608,558

1,986,692

44.2

2008

1,376,276

607,357

1,983,633

44.1

2009

1,410,033

629,828

2,039,861

44.7

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.
** Excludes Program Evaluation Assessment of $1,216,000.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 1999–2009

NHLBI Research Project Grants*:  Average Costs, Fiscal Years 1998-2008
Text-only with data points are represented in the table below.

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.

NHLBI Research Project Grants:*  Average Costs, Fiscal Years 1999–2009

Dollars (Thousands)

 

FY 1999

FY 2000

FY 2001

FY 2002

FY 2003

FY 2004

FY 2005

FY 2006

FY 2007

FY 2008

FY 2009

Noncompeting

$323.4

$346.6

$390.7

$418.8

$444.4

$458.7

$490.6

$503.9

$510.3

$512.4

$509.8

Competing

344.5

418.0

410.8

409.1

406.7

419.7

459.9

458.1

477.8

462.0

478.2

Total

$329.4

$366.6

$396.1

$416.2

$433.8

$447.9

$484.8

$492.8

$501.7

$501.8

$501.4

* Includes R01, U01, P01, R03, R15, R21, R29, R37, R41, R42, R43, and R44; R33 beginning in 2001; DP2 and U19 beginning in 2007; and DP1 and R00 beginning in 2008.

NHLBI Cooperative Agreements (U01, U10) Programs

Cooperative Agreements were instituted to support discrete, circumscribed projects in areas of an investigator's specific interest and competency with substantial programmatic participation by the NHLBI during performance of the activity.

 

Total Obligations Prior to FY 2009

Total FY 2009 Obligations

Total Obligations to Date

Heart and Vascular Diseases

 

 

 

AIM HIGH: Niacin Plus Statin to Prevent Vascular Events

$ 14,385,611

$ 1,132,517

$ 15,518,128

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D)

57,052,642

1,129,551

58,182,193

Cardiovascular Cell Therapy Research Network

11,992,445

6,226,923

18,219,368

Cardiovascular Heart Study (CHS) Events Follow-up Study

4,561,785

1,295,541

5,857,326

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)

21,413,274

21,413,274

Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillaton (CABANA) Trial

2,940,676

2,940,676

Claudication: Exercise Versus Endoluminal Revascularization

4,745,409

1,822,084

6,567,493

Clinical Research Consortium To Improve Resuscitation Outcomes

40,203,762

40,203,762

Community-Responsive Intervention To Reduce Cardiovascular Risk in American Indians and Alaska Natives

6,883,288

1,999,367

8,882,655

Dynamic Evaluation of Percutaneous Coronary Intervention

6,928,502

753,041

7,681,543

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN)

15,925,349

1,440,550

17,365,899

Heart Failure Clinical Research Network

21,256,277

7,938,673

29,194,950

Improved Measures of Diet and Physical Activity for the Genes and Environment Initiative

4,851,197

2,340,995

7,192,192

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine

14,689,861

3,210,240

17,900,101

NHLBI Cardiac Development Consortium

1,113,042

1,113,042

NHLBI Pediatric Cardiac Genomics Consortium

1,370,839

1,370,839

NHLBI Progenitor Cell Biology Consortium

22,721,547

22,721,547

Occluded Artery Trial (OAT)

19,953,495

1,269,829

21,223,324

Pediatric Heart Network

48,440,735

7,637,122

56,077,857

Pharmacogenetics Research Network

62,887,956

4,959,258

67,847,214

Practice-Based Opportunity for Weight Reduction (POWER) Trials

9,937,264

3,728,927

13,666,191

Programs of Excellence in Nanotechnology

39,522,116

11,279,810

50,801,926

Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II)

2,111,994

2,111,994

Strong Heart Study

69,831,832

1,026,776

70,858,608

Surgical Treatment for Ischemic Heart Failure (STICH)

38,081,071

726,648

38,807,719

Targeted Approaches to Weight Control for Young Adults

4,656,109

4,656,109

Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials

3,648,449

3,648,449

Translating Basic Behavioral and Social Science Discoveries Into Interventions to Reduce Obesity

5,431,213

5,431,213

Weight Loss Maintenance (WLM)

17,463,982

149,857

17,613,839

Subtotal, Heart and Vascular Diseases

531,007,853

104,061,578

635,069,431

Lung Diseases

 

 

 

Asthma Networks (AsthmaNet)

8,300,000

8,300,000

Childhood Asthma Management Program–Continuation Study (CAMP‑CS)/Phase III

4,043,232

1,145,547

5,188,779

COPD Clinical Research Network

40,030,386

3,150,000

43,180,386

Genetic Epidemiology of COPD

14,234,023

9,063,922

23,297,945

Idiopathic Pulmonary Fibrosis Clinical Research Network

25,205,892

7,324,944

32,530,836

Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS)

732,476

736,708

1,469,184

Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV‑Uninfected Controls

5,390,250

5,390,250

Pharmacogenetics of Asthma Treatment

23,813,429

3,192,109

27,005,538

Randomized Controlled Study of Adenotonsillectomy for Childhood Sleep Apnea

6,000,740

2,500,880

8,501,620

Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma

2,510,267

2,510,267

Sedation Management in Pediatric Patients With Acute Respiratory Failure

567,715

3,884,512

4,452,227

Study of Acid Reflux Therapy for Children With Asthma

2,462,212

882,798

3,345,010

Study of Asthma and Nasal Steroids (STAN)

724,724

724,724

Study of Soy Isoflavones in Asthma (SOYA)

774,607

774,607

Trial of Late Surfactant To Prevent Bronchopulmonary Dysplasia (TOLSURF)

1,986,898

1,986,898

Subtotal, Lung Diseases

117,090,105

51,568,166

168,658,271

Blood Diseases and Resources

 

 

 

Blood and Marrow Transplant Clinical Research Network

50,147,120

6,350,697

56,497,817

Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial

4,632,060

5,673,071

10,305,131

Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT–ATTRACT Trial

2,070,898

2,107,633

4,178,531

Stroke With Transfusions Changing to Hydroxyurea (SWITCH)

14,636,993

3,215,757

17,852,750

Thalassemia (Cooley’s Anemia) Clinical Research Network

22,006,021

657,580

22,663,601

Transfusion Medicine/Hemostasis Clinical Research Network

43,909,114

6,541,087

50,450,201

Subtotal, Blood Diseases and Resources

137,402,206

24,545,825

161,948,031

Total, NHLBI Cooperative Agreements

$785,500,164

$180,175,569

$965,675,733

Back to Top

Heart and Vascular Diseases Program

AIM HIGH: Niacin Plus Statin To Prevent Vascular Events, Initiated in Fiscal Year 2005

The purpose of this multicenter clinical trial is to determine whether extended-release niacin plus simvastatin is superior to simvastatin alone, at comparable levels of in-treatment LDL cholesterol, for preventing or delaying a major CVD event over a 4-year median followup period in patients with atherogenic dyslipidemia. Niacin is used to raise HDL ("good") cholesterol and simvastatin is used to lower LDL ("bad") cholesterol.

Obligations

Funding History:
Fiscal Year 2009—$1,132,517
Fiscal Years 2005–2008— $14,385,611
Total Funding to Date—$15,518,128

Current Active Organizations and Grant Numbers

  1. University of Washington
    Seattle, Washington —HL-081616
  2. AXIO Research, LLC
    Seattle, Washington —HL-081649

Bypass Angioplasty Revascularization Investigation in Type 2 Diabetics (BARI 2D), Initiated in Fiscal Year 2000

The purpose of this trial is to compare alternative treatment strategies for managing patients with type 2 diabetes and angiographically proven coronary artery disease, stable angina, or ischemia. Revascularization combined with aggressive medical anti-ischemia treatment is being compared to aggressive medical anti-ischemia treatment alone. Simultaneously, researchers seek to determine whether insulin-sensitizing drugs such as metformin and the glitazones for controlling blood sugar level offer any survival advantage over drugs that increase insulin level. One-third of the patients are from minority populations.

Research findings indicate that neither prompt revascularization versus delayed revascularization or insulin sensitization versus insulin provision in patients with type 2 diabetes and stable CHD was superior in terms of mortality and the prevention of major cardiovascular events.

Obligations

Funding History:
Fiscal Year 2009—$1,129,551
Fiscal Years 2000–2008—$57,052,642
Total Funding to Date—$58,182,193

Current Active Organization and Grant Number

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-061744

Cardiovascular Cell Therapy Research Network, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

Cardiovascular Heart Study (CHS) Events Follow-Up Study, Initiated in Fiscal Year 2005

The purpose of this project is to continue follow-up of the CHS cohort for cardiovascular events in order to enhance power among subgroups to study associations of CVD risk factors and incidence and prognosis following CVD events in older adults. The additional events will permit greater opportunity to address the study aims by CHS investigators and other researchers interested in making use of the study's extensive database and specimens. Seventeen percent of the participants are from minority populations.

Obligations

Funding History:
Fiscal Year 2009—$1,295,541
Fiscal Years 2005–2008—$4,561,785
Total Funding to Date—$5,857,326

Current Active Organization and Grant Number

  1. University of Washington
    Seattle, Washington —HL-080295

Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL), Initiated in Fiscal Year 2004

The purpose of this trial is to determine whether revascularization of a stenotic renal artery plus medical therapy is associated with improved clinical outcomes compared with medical therapy alone.

Obligations

Funding History:
Fiscal Year 2009—$0
Fiscal Years 2004–2008—$21,413,274
Total Funding to Date—$21,413,274

Current Active Organizations and Grant Numbers

  1. University of Toledo Health
    Sciences Campus
    Toledo, Ohio —HL-071556
  2. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-072734
  3. University of Virginia
    Charlottesville, Virginia —HL-072735
  4. Mid-America Heart Institute of
    St. Luke Hospital
    Kansas City, Missouri —HL-072736
  5. Beth Israel Deaconess Medical Center
    Boston, Massachusetts —HL-072737

Catheter Ablation Versus Antiarrythmic Drug Therapy for Atrial Fibrillation (CABANA), Initiated in Fiscal Year 2009

The purpose of this trial is to determine whether percutaneous left atrial catheter ablation is superior to current pharmacologic therapy for eliminating atrial fibrillation.

Obligations

Funding History:
Fiscal Year 2009—$2,940,676
Total Funding to Date—$2,940,676

Current Active Organizations and Grant Numbers

  1. Mayo Clinic, College of Medicine
    Rochester, Minnesota —HL-089645
  2. Mayo Clinic, College of Medicine
    Rochester, Minnesota —HL-089709
  3. Duke University
    Durham, North Carolina —HL-089786
  4. Duke University
    Durham, North Carolina —HL-089907

Claudication: Exercise Versus Endoluminal Revascularization, Initiated in Fiscal Year 2005

The purpose of this study is to test the hypothesis that a strategy of aortoiliac stenting and pharmacotherapy improves maximum walking duration better than a strategy of supervised rehabilitation, exercise, and pharmacotherapy for those with aortoiliac artery obstruction at 6 months. Other objectives are to compare the two treatment groups with a third group, usual care and pharmacotherapy, at 6 months, and to compare maximum walking duration change scores at 18 months, changes in free living daily activity levels, and patient-perceived quality of life among all three groups.

Obligations

Funding History:
Fiscal Year 2009—$1,822,084
Fiscal Years 2005–2008—$4,745,409
Total Funding to Date—$6,567,493

Current Active Organizations and Grant Numbers

  1. Rhode Island Hospital
    Providence, Rhode Island —HL-077221
  2. Beth Israel Deaconess Medical Center
    Boston, Massachusetts —HL-081656

Clinical Research Consortium To Improve Resuscitation Outcomes, Initiated in Fiscal Year 2004

See Chapter 11. Clinical Trials.

Community-Responsive Intervention To Reduce Cardiovascular Risk in American Indians and Alaska Natives, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Dynamic Evaluation of Percutaneous Coronary Intervention, Initiated in Fiscal Year 1997

This program, which complements prior NHLBI percutaneous transluminal coronary angioplasty (PTCA) registries and the New Approaches to Coronary Intervention Registry, is evaluating patterns of device usage, as well as immediate and follow-up outcomes in patients undergoing percutaneous transluminal coronary revascularization. Results will provide guidance to the cardiology community in selecting appropriate therapies and in designing clinical trials to evaluate competing devices.

Obligations

Funding History:
Fiscal Year 2009—$753,041
Fiscal Years 1997–2008—$6,928,502
Total Funding to Date—$7,681,543

Current Active Organization and Grant Number

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-033292

Genetics of Coronary Artery Disease in Alaska Natives (GOCADAN), Initiated in Fiscal Year 2000

The purpose of this study is to document CVD and CVD risk factors in approximately 40 extended families (1,214 members from villages in Northern Alaska). Scientists seek to identify and characterize genes that contribute to CVD in this unique and understudied population.

Obligations

Funding History:
Fiscal Year 2009—$1,440,550
Fiscal Years 2000–2008—$15,925,349
Total Funding to Date—$17,365,899

Current Active Organizations and Grant Numbers

  1. MedStar Research Institute
    Hyattsville, Maryland —HL-064244
  2. Norton Sound Health Corporation
    Nome, Alaska —HL-082458
  3. Southwest Foundation for
    Biomedical Research
    San Antonio, Texas —HL-082490

Heart Failure Clinical Research Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Improved Measures of Diet and Physical Activity for the Genes and Environment Initiative, Initiated in Fiscal Year 2007

The purpose of this program is to support the development of devices to improve diet and physical activity. The program is part of the Genes and Environment Initiative, a 4-year NIH-wide program designed to lay the foundation for understanding the complex interplay between genetic and environmental factors in human diseases.

Obligations

Funding History:
Fiscal Year 2009—$2,340,995
Fiscal Years 2007–2008—$4,851,197
Total Funding to Date—$7,192,192

Current Active Organizations and Grant Numbers

  1. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-091736
  2. Massachusetts Institute of Technology
    Cambridge, Massachusetts —HL-091737
  3. Princeton Multimedia Technologies
    Corporation
    Princeton, New Jersey —HL-091738

Network for Cardiothoracic Surgical Investigation in Cardiovascular Medicine, Initiated in Fiscal Year 2007

See Chapter 11. Clinical Trials.

NHLBI Cardiac Development Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to gain complete understanding of the regulatory networks controlling cardiovascular development. A consortium of multidisciplinary research teams will select key regulatory pathways, identify components of the pathways and targets, and rapidly disseminate data to the scientific community. Research results may lead to the development of regenerative therapies and tissue engineering approaches.

Obligations

Funding History:
Fiscal Year 2009—$1,113,042
Total Funding to Date—$1,113,042

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah —HL-098160
  2. Harvard University Medical School
    Boston, Massachusetts —HL-098166
  3. J. David Gladstone Institutes
    San Francisco, California —HL-098179
  4. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-098180

NHLBI Pediatric Cardiac Genomics Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to conduct clinical and translational research on the genetic causes of congenital heart disease and genetic contributions to outcome in individuals with congenital heart disease.

Obligations

Funding History:
Fiscal Year 2009—$1,370,839
Total Funding to Date—$1,370,839

Current Active Organizations and Grant Numbers

  1. Mount Sinai School of Medicine
    New York, New York —HL-098123
  2. Children's Hospital Boston
    Boston, Massachusetts —HL-098147
  3. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-098153
  4. Yale University
    New Haven, Connecticut —HL-098162
  5. Columbia University Health Sciences
    New York, New York —HL-098163

NHLBI Progenitor Cell Biology Consortium, Initiated in Fiscal Year 2009

The purpose of this study is to establish virtual research hubs that focus on progenitor cell biology. Investigators will seek to identify and characterize progenitor cell lineages, direct the differentiation of stem and progenitor cells to desired cell fates, and develop new strategies to address the unique challenges presented by the transplantation of these cells.

Obligations

Funding History:
Fiscal Year 2009—$22,721,547
Total Funding to Date—$22,721,547

Current Active Organizations and Grant Numbers

  1. Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania —HL-099656
  2. University of Wisconsin, Madison
    Madison, Wisconsin —HL-099773
  3. Johns Hopkins University
    Baltimore, Maryland —HL-099775
  4. Stanford University
    Stanford, California —HL-099776
  5. Fred Hutchinson Cancer Research Center
    Seattle, Washington —HL-099993
  6. Stanford University
    Stanford, California —HL-099995
  7. Stanford University
    Stanford, California —HL-099999
  8. Children's Hospital Boston
    Boston, Massachusetts —HL-100001
  9. Fred Hutchinson Cancer Research Center
    Seattle, Washington —HL-100395
  10. Stanford University
    Stanford, California —HL-100397
  11. Vanderbilt University
    Nashville, Tennessee —HL-100398
  12. University of Texas Southwestern
    Medical Center
    Dallas, Texas —HL-100401
  13. Massachusetts General Hospital
    Boston, Massachusetts —HL-100402
  14. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-100405
  15. J. David Gladstone Institutes
    San Francisco, California —HL-100406
  16. University of Minnesota, Twin Cities
    Minneapolis, Minnesota —HL-100407
  17. Massachusetts General Hospital
    Boston, Massachusetts —HL-100408

Occluded Artery Trial (OAT), Initiated in Fiscal Year 1999

The purpose of this study is to determine whether percutaneous revascularization to open an occluded artery within a few days or as long as a month following an acute MI in asymptomatic patients improves their outcome. Although the benefits of early restoration of blood flow following an acute MI have been well-established, it is not known whether later intervention is also beneficial. The trial is in a long-term followup phase.

Obligations

Funding History:
Fiscal Year 2009—$1,269,829
Fiscal Years 1999–2008—$19,953,495
Total Funding to Date—$21,223,324

Current Active Organizations and Grant Numbers

  1. New York University
    School of Medicine
    New York, New York —HL-062509
  2. Maryland Medical Research
    Institute, Inc.
    Baltimore, Maryland —HL-062511

Pediatric Heart Network, Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Pharmacogenetics Research Network, Initiated in Fiscal Year 2001

The purpose of this study is to establish a network to systematically evaluate candidate genes that may influence pharmacologic response to drug treatments for arrhythmia, heart failure, hypertension, and lipid disorders. Investigators seek to identify gene polymorphisms capable of predicting drug toxicity and efficacy. One of the projects has 38 percent minority participation.

Obligations

Funding History:
Fiscal Year 2009—$4,959,258
Fiscal Years 2001–2008—$62,887,956
Total Funding to Date—$67,847,214

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-065962
  2. Children's Hospital and Research Center
    Oakland, California —HL-069757

Practice-Based Opportunity for Weight Reduction (POWER) Trials,* Initiated in Fiscal Year 2006

See Chapter 11. Clinical Trials.

Programs of Excellence in Nanotechnology, Initiated in Fiscal Year 2005

The purpose of this program is to establish multidisciplinary teams to develop nanotechnology and biomolecular engineering tools and methodologies to detect and analyze atherosclerotic plaque formation. The program presents an unique opportunity for research collaboration and skills training by bring bioengineering and nanotechnology solutions into medicine and vice versa.

Obligations

Funding History:
Fiscal Year 2009—$11,279,810
Fiscal Years 2005–2008—$39,522,116
Total Funding to Date—$50,801,926

Current Active Organizations and Grant Numbers

  1. Emory University
    Atlanta, Georgia —HL-080711
  2. Burnham Institute for Medical Research
    La Jolla, California —HL-080718
  3. Washington University
    St. Louis, Missouri —HL-080729
  4. Massachusetts General Hospital
    Boston, Massachusetts —HL-080731

*Formerly known as Weight-Loss in Obese Adults with Cardiovascular Risk Factors.

Rule Out Myocardial Infarction Using Computed Assisted Tomography (ROMICAT II), Initiated in Fiscal Year 2009

The purpose of this study is to determine whether implementation of cardiac computed assisted tomography early in the emergency department triage process will enable immediate and safe discharge without further testing of a significant number of patients with acute chest pain.

Obligations

Funding History:
Fiscal Year 2009—$2,111,994
Total Funding to Date—$2,111,994

Current Active Organizations and Grant Numbers

  1. Massachusetts General Hospital
    Boston, Massachusetts —HL-092022
  2. Massachusetts General Hospital
    Boston, Massachusetts —HL-092040

Strong Heart Study, Initiated in Fiscal Year 1988

The objectives of this study are to survey CVD morbidity and mortality rates among three geographically diverse groups of American Indians and to estimate their levels of CVD risk factors. Phases II and III of the cohort study extended surveillance of community mortality and assessed development of CVD and changes in CVD risk factors. In Phase III, investigators added a substudy of asthma and a pilot family study. Phase IV expanded the family study to 120 families comprising 3,600 members to investigate genetic and environmental contributors of CVD. Phase V will examine the family study cohort to assess genetic relationships to risk factor change over a 5‑year period.

Obligations

Funding History:
Fiscal Year 2009—$1,026,776
Fiscal Years 1988–2008—$69,831,832
Total Funding to Date—$70,858,608

Current Active Organization and Grant Number

  1. Southwest Foundation for
    Biomedical Research
    San Antonio, Texas —HL-065520

Surgical Treatment for Ischemic Heart Failure (STICH), Initiated in Fiscal Year 2002

The purpose of this clinical trial is to determine whether CABG plus intensive medical therapy improves long-term survival of patients with heart failure and left ventricular (LV) dysfunction who have coronary artery disease amenable to surgical revascularization, compared to medical therapy alone; and to determine whether CABG plus surgical ventricular restoration to a more normal LV size improves survival free of subsequent hospitalizations of patients with anterior LV dysfunction, compared to CABG alone.

Obligations

Funding History:
Fiscal Year 2009—$726,648
Fiscal Years 2002–2008—$38,081,071
Total Funding to Date—$38,807,719

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-069013
  2. Duke University
    Durham, North Carolina —HL-069015

Targeted Approaches to Weight Control for Young Adults, Initiated in Fiscal Year 2009

See Chapter 11. Clinical Trials

Therapeutic Hypothermia After Pediatric Cardiac Arrest (THAPCA) Trials, Initiated in Fiscal Year 2009

The purpose of this program is to determine whether therapeutic hypothermia after pediatric cardiac arrest improves outcomes, including survival, in infants and children.

Obligations

Funding History:
Fiscal Year 2009—$3,648,449
Total Funding to Date—$3,648,449

Current Active Organizations and Grant Numbers

  1. University of Utah
    Salt Lake City, Utah —HL-094339
  2. University of Michigan at Ann Arbor
    Ann Arbor, Michigan —HL-094345

Translating Basic Behavioral and Social Science Discoveries Into Interventions To Reduce Obesity, Initiated in Fiscal Year 2009

The purpose of this study is to develop innovative obesity-reducing strategies rather than evaluating the effectiveness of already well-defined or proven strategies. Some projects are expected to have 50- to 100-percent participation from minorities. The new strategies should be effective in small-scale trials, acceptable to target populations of interest, and ready to be tested in large-scale randomized clinical and community trials.

Obligations

Funding History:
Fiscal Year 2009—$5,431,213
Total Funding to Date—$5,431,213

Current Active Organizations and Grant Numbers

  1. Claremont Graduate University
    Claremont, California —HL-097839
  2. Weill Medical College of
    Cornell University
    New York, New York —HL-097843
  3. Wayne State University
    Detroit, Michigan —HL-097889
  4. Rush University Medical Center
    Chicago, Illinois —HL-097894
  5. University of California, San Francisco
    San Francisco, California —HL-097973

Weight Loss Maintenance (WLM), Initiated in Fiscal Year 2003

The purpose of this multicenter trial is to evaluate the effectiveness of two strategies to maintain weight loss for 2.5 years in approximately 1,700 overweight or obese adults. Of those, 1,032 who lost at least 9 pounds during a 6-month weight loss program were randomized into one of three maintenance groups: brief monthly personal counseling on diet and physical activities; Web-based intervention providing similar advice; or self-directed control, where participants received minimal further intervention. Approximately 40 percent of participants were black.

The majority of individuals who successfully completed an initial behavioral weight loss program maintained a weight below their initial level. Monthly brief personal contact provided modest benefits to sustaining weight loss, whereas an interactive technology-based intervention provided early but transient benefits.

Obligations

Funding History:
Fiscal Year 2009—$149,857
Fiscal Years 2003–2008—$17,463,982
Total Funding to Date—$17,613,839

Current Active Organization and Grant Number

  1. Kaiser Foundation Research Institute
    Oakland, California —HL-068676

Lung Diseases Program

Asthma Networks (AsthmaNet)

See Chapter 11. Clinical Trials.

Childhood Asthma Management Program–Continuation Study (CAMP–CS)/Phase III, Initiated in Fiscal Year 2007

The objective of this observational study is to follow the original CAMP cohort for 4 more years (through ages 21–29) to determine clinical and genetic risk factors for patterns of lung function decline indicative of chronic air flow obstruction in later adulthood; 31 percent of the participants are from minority groups.

Obligations

Funding History:
Fiscal Year 2009—$1,145,547
Fiscal Years 2007–2008—$4,043,232
Total Funding to Date—$5,188,779

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-075232
  2. Hospital for Sick Children
    Toronto, Ontario —HL-075407
  3. Johns Hopkins University
    Baltimore, Maryland —HL-075408
  4. Asthma, Inc.
    Seattle, Washington —HL-075409
  5. University of California, San Diego
    La Jolla, California —HL-075415
  6. National Jewish Medical
    and Research Center
    Denver, Colorado —HL-075416
  7. Johns Hopkins University
    Baltimore, Maryland —HL-075417
  8. Brigham and Women's Hospital
    Boston, Massachusetts —HL-075419
  9. University of New Mexico
    Albuquerque, New Mexico —HL-075420

COPD Clinical Research Network, Initiated in Fiscal Year 2003

See Chapter 11. Clinical Trials.

Genetic Epidemiology of COPD, Initiated in Fiscal Year 2007

The purpose of this study is to perform a genome-wide association analysis to identify the genetic risk factors that determine susceptibility for COPD and COPD-related phenotypes in a large biracial population.

Obligations

Funding History:
Fiscal Year 2009—$9,063,922
Fiscal Years 2007–2008—$14,234,023
Total Funding to Date—$23,297,945

Current Active Organizations and Grant Numbers

  1. Brigham and Women's Hospital
    Boston, Massachusetts —HL-089856
  2. National Jewish Medical and
    Research Center
    Denver, Colorado —HL-089897

Idiopathic Pulmonary Fibrosis Clinical Research Network, Initiated in Fiscal Year 2005

See Chapter 11. Clinical Trials.

Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS), Initiated in Fiscal Year 2008

The purpose of this randomized clinical trial is to assess the efficacy and safety of 7 percent hypertonic saline (HS) inhaled twice daily for 48 weeks among infants with CF aged 4 to 15 months at enrollment. Investigators are seeking to determine whether hypertonic saline will improve hyperinflation and obstructive lung disease as measured by infant lung function testing compared with the control agent (isotonic saline).

Obligations

Funding History:
Fiscal Year 2009—$736,708
Fiscal Year 2008—$732,476
Total Funding to Date—$1,469,184

Current Active Organizations and Grant Numbers

  1. Children's Hospital and Regional
    Medical Center
    Seattle, Washington —HL-092931
  2. University of Washington
    Seattle, Washington —HL-092932

Microbiome of the Lung and Respiratory Tract in HIV-Infected Individuals and HIV-Uninfected Controls, Initiated in Fiscal Year 2009

The purpose of this study is to characterize the microbiome of the lung alone or in combination with the upper airways in HIV-infected individuals and matched HIV-uninfected controls. Investigators will use molecular techniques to identify bacteria, and if possible, other organisms (e.g., viruses, cell-wall deficient organisms, protozoa, and fungi). Data will be used to examine the effects of changes in the respiratory microbiome on the pathogenesis and progression of HIV disease, HIV-related respiratory complications, and anti-HIV therapies.

Obligations

Funding History:
Fiscal Year 2009—$5,390,250
Total Funding to Date—$5,390,250

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-098957
  2. George Washington University
    Washington, DC —HL-098958
  3. Indiana University-Purdue University
    at Indianapolis
    Indianapolis, Indiana —HL-098960
  4. University of Michigan at Ann Arbor
    Ann Arbor, Michigan —HL-098961
  5. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-098962
  6. University of California, San Francisco
    San Francisco, California —HL-098964
  7. University of Colorado
    Denver, Colorado —HL-098966

Pharmacogenetics of Asthma Treatment, Initiated in Fiscal Year 2000

The objective of this project is to bring together research experts in asthma, epidemiology, statistics, bioinformatics, physiology, clinical trials, genetics, and genomics to focus on the pharmacogenetics of asthma treatment.

Obligations

Funding History:
Fiscal Year 2009—$3,192,109
Fiscal Years 2000–2008— $23,813,429
Total Funding to Date—$27,005,538

Current Active Organization and Grant Number

  1. Brigham and Women's Hospital
    Boston, Massachusetts —HL-065899

Randomized Controlled Study of Adenotonsillectomy for Childhood Sleep Apnea, Initiated in Fiscal Year 2006

The purpose of this randomized controlled study is to compare adenotonsillectomy and watchful waiting followed by reevaluation after 7 months for treatment of OSA in children aged 5 to 9 years; 50 percent of the participants are expected to be black.

Obligations

Funding History:
Fiscal Year 2009—$2,500,880
Fiscal Years 2006–2008—$6,000,740
Total Funding to Date—$8,501,620

Current Active Organizations and Grant Numbers

  1. Case Western Reserve University
    Cleveland, Ohio —HL-083075
  2. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-083129

Randomized Trial of Maternal Vitamin D Supplementation To Prevent Childhood Asthma, Initiated in Fiscal Year 2009

The purpose of this randomized clinical trial is to determine whether higher vitamin D intake and increased levels in a pregnant woman will prevent asthma and allergy in her child at age 3. Investigators will recruit 870 pregnant women who are in the first trimester of pregnancy. This sample will be randomized to one of two treatment arms of a 4-year clinical trial: 4,000 international units of vitamin D in addition to typical prenatal vitamins and typical prenatal vitamins alone.

Obligations

Funding History:
Fiscal Year 2009—$2,510,267
Total Funding to Date—$2,510,267

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-091075
  2. Brigham and Women's Hospital
    Boston, Massachusetts —HL-091528

Sedation Management in Pediatric Patients With Acute Respiratory Failure, Initiated in Fiscal Year 2008

The purpose of this randomized clinical trial is to test an innovative approach to sedation management that includes team education and consensus on the use of sedatives in pediatric patients supported on mechanical ventilation; team identification of each patient's trajectory of illness and daily prescription of a sedation goal; use of a nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines; and team feedback on sedation management performance. Investigators will randomize 2,754 critically ill infants and children into two study groups: sedation management intervention and usual care.

Obligations

Funding History:
Fiscal Year 2009—$3,884,512
Fiscal Year 2008—$567,715
Total Funding to Date—$4,452,227

Current Active Organizations and Grant Numbers

  1. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-086622
  2. Children's Hospital Boston
    Boston, Massachusetts —HL-086649

Study of Acid Reflux Therapy for Children With Asthma, Initiated in Fiscal Year 2006

The purpose of this randomized controlled clinical trial is to investigate whether an approved proton-pump inhibitor lansoprazole will reduce asthma exacerbations in children (aged 6–16 years) with poorly controlled asthma. Thirty percent of participants will be from minority populations.

Obligations

Funding History:
Fiscal Year 2009—$882,798
Fiscal Years 2006–2008—$2,462,212
Total Funding to Date—$3,345,010

Current Active Organizations and Grant Numbers

  1. Emory University
    Atlanta, Georgia —HL-080433
  2. Johns Hopkins University
    Baltimore, Maryland —HL-080450

Study of Asthma and Nasal Steroids (STAN), Initiated in Fiscal Year 2009

The purpose of this clinical trial is to determine whether the addition of treatment of chronic rhinitis and sinusitis with a nasal steroid will improve asthma control. Investigators will randomize 380 patients with poorly controlled asthma and chronic rhinitis/sinusitis to a nasal steroid or matching placebo in addition to their regular asthma treatment. One third of participants are expected to be from minority populations.

Obligations

Funding History:
Fiscal Year 2009—$724,724
Total Funding to Date—$724,724

Current Active Organizations and Grant Numbers

  1. University of Vermont
    Burlington, Vermont —HL-089464
  2. Johns Hopkins University
    Baltimore, Maryland —HL-089510

Study of Soy Isoflavones in Asthma (SOYA), Initiated in Fiscal Year 2009

The purpose of this double-blind, randomized controlled trial is to assess the effectiveness of genistein supplements (soy isoflavone) in improving lung function in patients with poorly controlled asthma. The study will include 380 patients with low dietary soy intake, ages 12 years and older, who are taking inhaled corticosteroids, leukotriene modifiers, or both and have poorly controlled asthma. Participants will be randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein, and glycitein) 100 mg daily or to placebo for 6 months. Thirty percent of participants are expected to be from minority populations.

Obligations

Funding History:
Fiscal Year 2009—$774,607
Total Funding to Date—$774,607

Current Active Organizations and Grant Numbers

  1. Northwestern University
    Evanston, Illinois —HL-087987
  2. Johns Hopkins University
    Baltimore, Maryland —HL-088367

Trial of Late Surfactant To Prevent Bronchopulmonary Dysplasia (TOLSURF), Initiated in Fiscal Year 2009

The purpose of this randomized controlled clinical trial is to determine whether late doses of surfactant, in addition to iNO, administered to extremely low gestational age neonates (< 30 weeks) who require mechanical ventilation between 7 and 14 days of age, will increase survival without bronchopulmonary dysplasia.

Obligations

Funding History:
Fiscal Year 2009—$1,986,898
Total Funding to Date—$1,986,898

Current Active Organizations and Grant Numbers

  1. University of California, San Francisco
    San Francisco, California —HL-094338
  2. University of California, San Francisco
    San Francisco, California —HL-094355

Blood Diseases and Resources

Blood and Marrow Transplant Clinical Research Network, Initiated in Fiscal Year 2001

See Chapter 11. Clinical Trials.

Bridging Anticoagulation on Patients Requiring Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery (BRIDGE) Trial, Initiated in Fiscal Year 2008

The purpose of this study is to determine the safety and efficacy of low molecular weight heparin (LMWH) in adults with atrial fibrillation who stop warfarin in preparation for surgery. The trial will randomly allocate 3,282 patients with atrial fibrillation to either LMWH or matching placebo before and after surgery. Investigators hypothesize that simply withholding warfarin in a perioperative setting for patients with atrial fibrillation will not meaningfully increase the risk for arterial thromboembolism and will forestall hemorrhagic complications, compared with a strategy using LMWH before and after surgery. One third of participants are expected to be from minority populations.

Obligations

Funding History:
Fiscal Year 2009—$5,673,071
Fiscal Year 2008—$4,632,060
Total Funding to Date—$10,305,131

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-86755
  2. Duke University
    Durham, North Carolina —HL-87229

Pharmacomechanical Catheter-Directed Thrombolysis for Acute DVT–ATTRACT Trial, Initiated in Fiscal Year 2008

The purpose of this study is to determine whether adjunctive pharmacomechanical catheter-directed thrombolysis, which includes intrathrombus administration of recombinant tissue plasminogen activator, can prevent postthrombotic syndrome in patients with symptomatic proximal deep vein thrombosis (DVT) compared with optimal standard DVT therapy alone.

Obligations

Funding History:
Fiscal Year 2009—$2,107,633
Fiscal Year 2008—$2,070,898
Total Funding to Date—$4,178,531

Current Active Organizations and Grant Numbers

  1. McMaster University
    Hamilton, Ontario —HL-088118
  2. Washington University
    St. Louis, Missouri —HL-088476

Stroke With Transfusions Changing to Hydroxyurea (SWITCH), Initiated in Fiscal Year 2005

The purpose of this Phase III clinical trial is to compare standard therapy (transfusions and chelation) with alternative therapy (hydroxyurea and phlebotomy) for the prevention of secondary stroke and management of iron overload in children with sickle cell anemia. Additional objectives include comparisons of growth and development, frequency of nonstroke neurological and other sickle-related events, and quality of life. Participants will be black.

Obligations

Funding History:
Fiscal Year 2009—$3,215,757
Fiscal Years 2005–2008—$14,636,993
Total Funding to Date—$17,852,750

Current Active Organizations and Grant Numbers

  1. St. Jude Children's Research Hospital
    Memphis, Tennessee —HL-078787
  2. Rho Federal Systems Division, Inc.
    Chapel Hill, North Carolina —HL-078987

Thalassemia (Cooley's Anemia) Clinical Research Network, Initiated in Fiscal Year 2000

See Chapter 11. Clinical Trials.

Transfusion Medicine/Hemostasis Clinical Research Network, Initiated in Fiscal Year 2002

See Chapter 11. Clinical Trials.

NHLBI Research Centers (P50) Programs

Specialized Centers of Clinically Oriented Research (P50)

The NHLBI initiated the Specialized Centers of Research (SCOR) program in 1971 to encourage translational research—converting basic science findings to the clinic—in high priority areas. The SCOR concept emphasized multidisciplinary research (i.e., basic science and clinical investigations) on diseases relevant to the Institute's mission. In 2002, the NHLBI revised the SCOR program—primarily on recommendation from the NHLBAC—to place more emphasis on clinical research projects. The SCCOR program still requires clinical and basic scientists to work together on a unified theme, but now requires at least 50 percent of the projects to be clinical. The SCOR program ended in 2008.

The funding history for individual SCCORs supported by the Institute is listed below.

Obligations (Dollars in Thousands)

Area of Concentration Period of Operation Prior to
FY 2009
FY 2009 Total to Date

Heart and Vascular Diseases Program

 

 

 

 

Cardiac Dysfunction and Disease (SCCOR)

2005–

$ 65,449

$13,486

$ 78,935

Vascular Injury, Repair, and Remodeling (SCCOR)

2006–

44,674

12,496

57,170

Subtotal, Heart and Vascular Diseases Program

 

110,123

25,982

136,105

Lung Diseases Program

 

 

 

 

Chronic Obstructive Pulmonary Disease (SCCOR)

2007–

22,236

11,228

33,464

Host Factors in Chronic Lung Diseases (SCCOR)

2006–

23,865

8,473

32,338

Pulmonary Vascular Disease (SCCOR)

2007–

12,732

6,480

19,212

Subtotal, Lung Diseases Program

 

58,833

26,181

85,014

Blood Diseases and Resources Program

 

 

 

 

Hemostatic and Thrombotic Diseases (SCCOR)

2006–

24,141

8,413

32,554

Transfusion Biology and Medicine (SCCOR)

2005–

17,818

4,651

22,469

Subtotal, Blood Diseases and Resources Program

 

41,959

13,064

55,023

Total, Specialized Centers of Clinically Oriented Research (P50)

 

$210,915

$65,227

$276,142

 

Heart and Vascular Diseases Program

Cardiac Dysfunction and Disease

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions related to dysfunction and disease of the myocardium. The program will enable rapid application of basic science findings to the prevention, diagnosis, and treatment of cardiac disorders, including ischemic and other cardiomyopathies, left ventricular dysfunction, metabolic abnormalities, heart failure, and rhythm disturbances. Because some segments of the population disproportionately suffer from heart disease, research that addresses issues of health disparity will be emphasized.

Obligations

Fiscal Year 2009—$13,486,219

Current Active Organizations and Grant Numbers

  1. Columbia University
    Health Science Center
    New York, New York —HL-077096
  2. University of Alabama at Birmingham
    Birmingham, Alabama —HL-077100
  3. University of Cincinnati
    Cincinnati, Ohio —HL-077101
  4. Cleveland Clinical Lerner College
    Cleveland, Ohio —HL-077107
  5. Washington University
    St. Louis, Missouri —HL-077113

Vascular Injury, Repair, and Remodeling

The purpose of this SCCOR is to foster multidisciplinary research on clinically relevant questions that will enable basic science findings to be more rapidly translated into clinical applications. Major goals of the program are to stimulate interdependent clinical and multidisciplinary basic research projects that investigate molecular and cellular mechanisms of vascular injury, repair, and remodeling; promote patient-oriented research that will improve our ability to prevent, detect, characterize, manage, and treat vascular diseases; and develop the skills and research capabilities of new clinical investigators.

Obligations

Fiscal Year 2009—$12,496,418

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-083762
  2. University of Texas Health
    Science Center
    Houston, Texas —HL-083794
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-083799
  4. Stanford University
    Stanford, California —HL-083800
  5. Boston University Medical Campus
    Boston, Massachusetts —HL-083801
  6. Beth Israel Deaconess Medical Center
    Boston, Massachusetts —HL-083813

Lung Diseases Program

Chronic Obstructive Pulmonary Disease

The purpose of this SCCOR is to foster multidisciplinary research to accelerate progress in the diagnosis, prevention, and treatment of COPD. The program will include a broad spectrum of basic and clinical research that will encompass animal models of COPD pathogenesis, human proteomic, genetic and genomic investigations, technologically refined disease phenotypes classification, and the development of new experimental therapeutic interventions.

Obligations

Fiscal Year 2009—$11,227,890

Current Active Organizations and Grant Numbers

  1. Washington University
    St. Louis, Missouri —HL-084922
  2. Weill Medical College
    of Cornell University
    New York, New York —HL-084936
  3. Johns Hopkins University
    Baltimore, Maryland —HL-084945
  4. University of Pittsburgh
    Pittsburgh, Pennsylvania —HL-084948

Host Factors in Chronic Lung Diseases

The purpose of this SCCOR is to identify alterations in host responses and lung homeostasis and to determine how the dysregulation contributes to development or progression of chronic lung diseases. Enhanced understanding of these processes should facilitate identification of new targets for intervention, providing the basis for development of new therapeutic options for prevention and treatment of chronic lung diseases.

Obligations

Fiscal Year 2009—$8,472,710

Current Active Organizations and Grant Numbers

  1. Duke University
    Durham, North Carolina —HL-084917
  2. Children's Hospital
    Pittsburgh, Pennsylvania —HL-084932
  3. University of North Carolina
    Chapel Hill, North Carolina —HL-084934

Pulmonary Vascular Disease

The objective of this SCCOR is to facilitate multidisciplinary research that proposes original hypotheses and applies cutting-edge approaches, including genomics and proteomics, to clinical issues in pulmonary vascular disease.

Obligations

Fiscal Year 2009—$6,480,043

Current Active Organizations and Grant Numbers

  1. University of Colorado at Denver
    Denver, Colorado —HL-084923
  2. Johns Hopkins University
    Baltimore, Maryland —HL-084946

Blood Diseases and Resources Program

Hemostatic and Thrombotic Diseases

The purpose of this SCCOR is to conduct multidisciplinary research to improve the prevention, diagnosis, and treatment of thrombotic and bleeding disorders. The program will support rapid translation of basic science findings into clinical application.

Obligations

Fiscal Year 2009—$8,412,822

Current Active Organizations and Grant Numbers

  1. Vanderbilt University
    Nashville, Tennessee —HL-081009
  2. Cleveland Clinic Lerner College
    Cleveland, Ohio —HL-081011
  3. University of Pennsylvania
    Philadelphia, Pennsylvania —HL-081012

Transfusion Biology and Medicine

The purpose of this SCCOR is to foster new approaches for improving the availability, efficacy, safety, and quality of blood and blood products for therapeutic uses. One of the centers has a large minority population.

Obligations

Fiscal Year 2009—$4,650,915

Current Active Organizations and Grant Numbers

  1. Puget Sound Blood Center
    Seattle, Washington —HL-081015
  2. University of California, San Francisco
    San Francisco, California —HL-081027

Basic and Translational Research Program (U54)

The NHLBI reconfigured the Comprehensive Sickle Cell Centers program into a Basic and Translational Research Program (BTRP). The Program emphasizes fundamental investigations and their translation into initial studies in humans, as well as community translation to promote evidence-based clinical practice. The BTRP continues to support the Sickle Cell Disease Scholars program for the career development of young investigators and the Summer-for-Sickle Cell-Science program for research training and mentoring of high-school students. These components are part of a larger effort by NHLBI to prepare the next generation of scientists to advance the field of SCD research.

Obligation

Fiscal Year 2009—$13,566,634

Current Active Organizations and Grant Numbers

  1. Thomas Jefferson University
    Philadelphia, Pennsylvania —HL-070585
  2. RHO Federal Systems Division, Inc.
    Chapel Hill, North Carolina —HL-070587
  3. University of Texas
    Southwestern Medical Center
    Dallas, Texas —HL-070588
  4. St. Jude Children's Research Hospital
    Memphis, Tennessee —HL-070590
  5. Boston Medical Center
    Boston, Massachusetts —HL-070819
  6. Children's Hospital Medical Center
    Cincinnati, Ohio —HL-070871
  7. Medical College of Wisconsin
    Milwaukee, Wisconsin —HL-090503
  8. Howard University
    Washington, DC —HL-090508
  9. Children's Hospital
    Los Angeles, California —HL-090511
  10. University of Chicago
    Chicago, Illinois —HL-090513
  11. Johns Hopkins University
    Baltimore, Maryland —HL-090515
  12. Virginia Commonwealth University
    Richmond, Virginia —HL-090516
  13. University of Miami School of Medicine
    Miami, Florida —HL-090569

Specialized Centers for Cell-Based Therapies for Heart, Lung, and Blood Diseases (U54) Program

The Specialized Centers for Cell-Based Therapies Program, which includes a Data and Coordinating Center, was initiated in FY 2005 to support preclinical and clinical studies for cell-based therapy for heart, lung, and blood diseases and sleep disorders. A key feature of the program is the ability to conduct preclinical studies in the first year or two of the program in order to meet the requirements for an Investigational New Drug application prior to initiating clinical studies. Clinical studies are expected to be initiated by the beginning of the third year.

Obligations

Fiscal Year 2009—$7,649,361

Current Active Organizations and Grant Numbers

  1. Baylor College of Medicine
    Houston, Texas —HL-081007
  2. EMMES Corporation
    Rockville, Maryland —HL-081021
  3. Cedars-Sinai Medical Center
    Los Angeles, California —HL-081028
  4. Massachusetts General Hospital
    Boston, Massachusetts —HL-081030

Centers for AIDS Research (P30) Program

The NHLBI, along with five other NIH Institutes, contributes to the support of six Centers for AIDS Research that were established to provide a multidisciplinary environment that promotes basic, clinical, behavioral, and translational research activities in the prevention, detection, and treatment of HIV infection and AIDS. Almost half of the patient population comes from minority groups.

Obligations

Fiscal Year 2009—$3,254,346

Current Active Organizations and Grant Numbers

  1. New York University
    School of Medicine
    New York, New York —AI-027742
  2. University of Washington
    Seattle, Washington —AI-027757
  3. University of California, San Francisco
    San Francisco, California —AI-027763
  4. University of Alabama at Birmingham
    Birmingham, Alabama —AI-027767
  5. University of California, Los Angeles
    Los Angeles, California —AI-028697
  6. Baylor University
    Houston, Texas —AI-036211
  7. University of California, San Diego
    La Jolla, California —AI-036214
  8. Case Western Reserve University
    Cleveland, Ohio —AI-036219
  9. University of Massachusetts
    Medical School
    Worcester, Massachusetts —AI-042845
  10. Miriam Hospital
    Providence, Rhode Island —AI-042853
  11. University of Pennsylvania
    Philadelphia, Pennsylvania —AI-045008
  12. Emory University
    Atlanta, Georgia —AI-050409
  13. University of North Carolina
    at Chapel Hill
    Chapel Hill, North Carolina —AI-050410
  14. Yeshiva University
    New York, New York —AI-051519
  15. Vanderbilt University
    Nashville, Tennessee —AI-054999
  16. Harvard Medical School
    Boston, Massachusetts —AI-060354
  17. Duke University
    Durham, North Carolina —AI-064518
  18. University of Miami
    School of Medicine
    Coral Gables, Florida —AI-073961
  19. University of Rochester
    Rochester, New York —AI-078498
  20. Rush University Medical Center
    Chicago, Illinois —AI-082151

Back to Top

« Back

Next »

Fact Book Table of Contents

Twitter iconTwitterimage of external icon Facebook iconFacebookimage of external icon YouTube iconYouTubeimage of external icon Google+ iconGoogle+image of external icon